Steven M Smith

Steven M Smith, Pharm.D., M.P.H.

Assistant Professor

Department: Pharmacotherapy & Translational Research
Business Phone: (352) 273-5134
Business Email: ssmith@cop.ufl.edu

About Steven M Smith

Steven Smith is an Assistant Professor in the Departments of Pharmacotherapy and Translational Research and Pharmaceutical Outcomes and Policy. He also serves as Associate Director for the UF Center for Integrative Cardiovascular and Metabolic Diseases.

He received his PharmD degree from the University of Florida College of Pharmacy. He then completed a PGY-1 residency at the North Florida/South Georgia Veterans Health System in Gainesville, FL. After his residency, Dr. Smith completed a postdoctoral fellowship in Family Medicine during which time he participated in the Advanced Postgraduate Program in Clinical Investigation (APPCI) and concurrently completed the requirements for a Master of Public Health. Dr. Smith joined the faculty at the University of Colorado in 2011. He returned to the University of Florida in 2014.

Dr. Smith’s research is in the area of cardiovascular pharmacotherapy and hypertension and is funded by the National Heart, Lung, and Blood Institute of the National Institutes of Health. He is a member of the American Heart Association, American College of Cardiology, American College of Clinical Pharmacy, the American Association of Colleges of Pharmacy and the International Society for Pharmacoepidemiology. He also serves in several leadership roles nationally, including on the Examination Committee for the American Society of Hypertension Specialists’ Program (ASHSP) Certified Hypertension Clinician program, in several initiatives through the American Heart Association Hypertension Council, on the Board of Directors for the Consortium for Southeastern Hypertension Control, and as a founding member of the CDC’s National Hypertension Control Roundtable.

Dr. Smith also co-directs the UF Family Medicine Pharmacy Fellowship (see link below).

Accomplishments

Excellence Award for Assistant Professors
2019 · University of Florida
Fellow
2018 · American College of Clinical Pharmacy
Delta Omega Inductee
2017 · University of Florida College of Public Health & Health Professions
Teaching and Service Excellence Award
2017 · University of Florida College of Pharmacy
New Investigator Award
2015 · American College of Clinical Pharmacy
Anniversary Fellow in Pharmacy
2014-2016 · National Academy of Medicine

Board Certifications

  • Board-Certified Pharmacotherapy Specialist
    Board of Pharmaceutical Specialties
  • Certified Hypertension Clinician
    American Hypertension Specialist Certification Program

Research Profile

Dr. Smith’s research lab focuses on understanding and improving use of cardiovascular-related drug therapy in the real world to reduce risk of major adverse outcomes at the population level. Hypertension and its treatment are the major area of focus, and Dr. Smith has particular expertise in the area of difficult-to-control, or ‘resistant’ hypertension.

His lab employs a variety of observational methodologic approaches and data sources, including EHR, administrative claims, and prospective cohort and randomized clinical trial data. Strong collaborations within the College of Pharmacy include with faculty and trainees in the Cardiovascular group of the Department of Pharmacotherapy and Translational Research, as well as with the Department of Pharmaceutical Outcomes and Policy and the Center for Drug Evaluation and Safety. Outside of the College, Dr. Smith’s group works closely with the Division of Cardiovascular Medicine and the Center for Integrative Cardiovascular and Metabolic Diseases, where Dr. Smith serves as Associate Director.

Current funding for the lab is through the National Heart, Lung and Blood Institute (NIH), and is focused on using integrated EHR and claims data to better understand what drives antihypertensive prescribing and effectiveness/safety issues with such drugs in the real world, and to use that information in developing predictive models for improving selection of initial antihypertensive therapy.

Open Researcher and Contributor ID (ORCID)

0000-0002-0201-839X

Areas of Interest
  • Cardiometabolic Disease
  • Cardiovascular Epidemiology
  • Hypertension
  • Pharmacoepidemiology
  • Resistant Hypertension

Publications

2021
Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans.
PloS one. 16(4) [DOI] 10.1371/journal.pone.0248080. [PMID] 33891615.
2021
Antihypertensive medication adherence trends by sex and drug class: A pilot study
American Heart Journal Plus: Cardiology Research and Practice. 5 [DOI] 10.1016/j.ahjo.2021.100023.
2021
Are novel glucose-lowering agents’ cardiorenal benefits generalizable to individuals of Black race? A meta-trial sequential analysis to address disparities in cardiovascular and renal outcome trials enrolment.
Diabetes, obesity & metabolism. [DOI] 10.1111/dom.14540. [PMID] 34472689.
2021
Association of 1-Year Blood Pressure Variability With Long-term Mortality Among Adults With Coronary Artery Disease: A Post Hoc Analysis of a Randomized Clinical Trial.
JAMA network open. 4(4) [DOI] 10.1001/jamanetworkopen.2021.8418. [PMID] 33914047.
2021
Effectiveness of Sacubitril/Valsartan Versus Aldosterone Antagonists in Heart Failure with reduced Ejection Fraction: A Retrospective Cohort Study.
Pharmacotherapy. [DOI] 10.1002/phar.2610. [PMID] 34170559.
2021
Experiences of Discrimination Are Associated With Worse Metabolic Syndrome Severity Among African Americans in the Jackson Heart Study.
Annals of behavioral medicine : a publication of the Society of Behavioral Medicine. 55(3):266-279 [DOI] 10.1093/abm/kaaa050. [PMID] 32686818.
2021
Fixed-dose combination amlodipine-celecoxib for treatment of hypertension and osteoarthritis pain: an up-to-date evaluation.
Expert opinion on pharmacotherapy. 22(11):1381-1385 [DOI] 10.1080/14656566.2021.1915289. [PMID] 33938788.
2021
Metabolomics Signature of Plasma Renin Activity and Linkage with Blood Pressure Response to Beta Blockers and Thiazide Diuretics in Hypertensive European American Patients.
Metabolites. 11(9) [DOI] 10.3390/metabo11090645. [PMID] 34564461.
2021
Newer drug treatments for type 2 diabetes.
BMJ (Clinical research ed.). 373 [DOI] 10.1136/bmj.n1171. [PMID] 33975861.
2021
Optimizing Precision of Hypertension Care to Maximize Blood Pressure Control: A Pilot Study Utilizing a Smartphone App to Incorporate Plasma Renin Activity Testing.
Clinical and translational science. 14(2):617-624 [DOI] 10.1111/cts.12922. [PMID] 33142006.
2021
Potential of Minocycline for Treatment of Resistant Hypertension.
The American journal of cardiology. 156:147-149 [DOI] 10.1016/j.amjcard.2021.07.004. [PMID] 34348841.
2021
U.S. trends in prescription nonsteroidal anti-inflammatory drug use among patients with cardiovascular disease, 1988-2016.
Pharmacotherapy. 41(3):247-256 [DOI] 10.1002/phar.2488. [PMID] 33231878.
2020
Adrenal Gland Disorders
Pharmacotherapy: A Pathophysiologic Approach. 11th Ed.:1291-1312
2020
Attended vs unattended systolic blood pressure measurement: A randomized comparison in patients with cardiovascular disease.
Journal of clinical hypertension (Greenwich, Conn.). 22(11):1987-1992 [DOI] 10.1111/jch.14037. [PMID] 32951360.
2020
Comparative effectiveness and safety of apixaban versus warfarin in patients with venous thromboembolism.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 77(3):188-195 [DOI] 10.1093/ajhp/zxz307. [PMID] 31974557.
2020
Comparative Effectiveness and Safety of Direct-acting Oral Anticoagulants and Warfarin in Patients with Venous Thromboembolism and Active Cancer: An Observational Analysis.
Clinical therapeutics. 42(9):e161-e176 [DOI] 10.1016/j.clinthera.2020.06.022. [PMID] 32768247.
2020
Comparative Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Response to a Physical Activity Intervention in Older Adults: Results From the Lifestyle Interventions and Independence for Elders Study.
The journals of gerontology. Series A, Biological sciences and medical sciences. 75(5):1010-1016 [DOI] 10.1093/gerona/glz120. [PMID] 31070702.
2020
Cushing Syndrome
Pharmacotherapy Casebook: A Patient-Focused Approach. 11th Ed.:239-240
2020
Optimal systolic blood pressure and reduced long-term mortality in older hypertensive women with prior coronary events – An analysis from INVEST☆
International Journal of Cardiology Hypertension. 7 [DOI] 10.1016/j.ijchy.2020.100052. [PMID] 33817619.
2020
Optimizing Antihypertensive Medication Classification in Electronic Health Record-Based Data: Classification System Development and Methodological Comparison.
JMIR Medical Informatics. 8(2) [DOI] 10.2196/14777. [PMID] 32130152.
2020
Osteoarthritis
Pharmacotherapy Principles & Practice Study Guide: A Case-Based Care Plan Approach. 5th Ed
2020
Out-of-Pocket Payment for Ambulatory Blood Pressure Monitoring Among Commercially Insured in the United States.
American journal of hypertension. 33(11):999-1002 [DOI] 10.1093/ajh/hpaa120. [PMID] 32930343.
2020
Redefining Resistant Hypertension: A Comparison of Cardiovascular Risk Associated With the 2018 Versus 2008 American Heart Association Definitions for Resistant Hypertension.
Circulation. Cardiovascular quality and outcomes. 13(2) [DOI] 10.1161/CIRCOUTCOMES.119.005979. [PMID] 32008359.
2020
Reimbursement of ambulatory blood pressure monitoring in the US commercial insurance marketplace.
Journal of clinical hypertension (Greenwich, Conn.). 22(1):6-15 [DOI] 10.1111/jch.13772. [PMID] 31873973.
2020
Risk and Blood Pressure Control Rates Across the Spectrum of Coronary Artery Disease in Hypertensive Women: An Analysis from The INternational VErapamil SR-Trandolapril STudy (INVEST).
Journal of women's health (2002). 29(2):158-166 [DOI] 10.1089/jwh.2018.7235. [PMID] 31403360.
2020
SGLT2 inhibitors and kidney outcomes in the real world.
BMJ (Clinical research ed.). 369 [DOI] 10.1136/bmj.m1584. [PMID] 32349997.
2020
Thiazide Exposure and Cardiovascular Risk in Type 2 Diabetes Mellitus: A Point of Clarification.
Hypertension (Dallas, Tex. : 1979). 75(3):e2-e5 [DOI] 10.1161/HYPERTENSIONAHA.119.14447. [PMID] 32008437.
2020
Trends in ambulatory blood pressure monitoring use for confirmation or monitoring of hypertension and resistant hypertension among the commercially insured in the U.S., 2008-2017.
International Journal of Cardiology. Hypertension. 6 [DOI] 10.1016/j.ijchy.2020.100033. [PMID] 33447762.
2020
Twelve-year trends in pharmacologic treatment of type 2 diabetes among patients with heart failure in the United States.
Diabetes, Obesity and Metabolism. 22(4):705-710 [DOI] 10.1111/dom.13949.
2019
Applying Literature to Patient Care
Principles of Research Design and Drug Literature Evaluation. 2nd Ed.:223-230
2019
ARB Superiority Over ACE Inhibitors in Coronary Heart Disease: An Alternative Viewpoint.
Pharmacotherapy. 39(2):204-206 [DOI] 10.1002/phar.2216. [PMID] 30633371.
2019
Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes.
Diabetes, Obesity and Metabolism. 21(1):28-36 [DOI] 10.1111/dom.13477.
2019
Erenumab: A First-in-Class Monoclonal Antibody for Migraine Prevention.
The Annals of pharmacotherapy. 53(9):933-939 [DOI] 10.1177/1060028019835166.
2019
Fixed-Dose Combination Amlodipine/Celecoxib (Consensi) for Hypertension and Osteoarthritis.
The American Journal of Medicine. 132(2):172-174 [DOI] 10.1016/j.amjmed.2018.08.027.
2019
Incidence, prevalence, and predictors of treatment-resistant hypertension with intensive blood pressure lowering.
Journal of clinical hypertension (Greenwich, Conn.). 21(6):825-834 [DOI] 10.1111/jch.13550. [PMID] 31066177.
2019
Partnering With Pharmacists to Reduce Cardiovascular Risk in Outpatient Settings.
Journal of the American Heart Association. 8(22) [DOI] 10.1161/JAHA.119.014705. [PMID] 31711389.
2019
The Reply.
The American journal of medicine. 132(7):e624-e625 [DOI] 10.1016/j.amjmed.2019.03.031. [PMID] 31400796.
2018
Betrixaban: A New Oral Factor Xa Inhibitor for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients.
The Annals of pharmacotherapy. 52(6):554-561 [DOI] 10.1177/1060028018754383. [PMID] 29338293.
2018
Evaluation of SAMe-TT2R2 Score on Predicting Success With Extended-Interval Warfarin Monitoring.
Annals of Pharmacotherapy. 52(11):1085-1090 [DOI] 10.1177/1060028018779774.
2018
Hypertension in Florida: Data From the OneFlorida Clinical Data Research Network.
Preventing chronic disease. 15 [DOI] 10.5888/pcd15.170332. [PMID] 29494332.
2018
Intensive blood pressure lowering reduces adverse cardiovascular outcomes among patients with high-normal glucose: An analysis from the Systolic Blood Pressure Intervention Trial database.
Journal of clinical hypertension (Greenwich, Conn.). 20(4):620-624 [DOI] 10.1111/jch.13247. [PMID] 29532983.
2018
Mortality implications associated with lower diastolic blood pressure when systolic pressure is reduced to new goals: Long-term follow-up of hypertensive patients with coronary artery disease in US cohort of International Verapamil (SR)-Trandolapril Study (INVEST)
. 36(2):419-427
2018
Mortality implications of lower DBP with lower achieved systolic pressures in coronary artery disease: long-term mortality results from the INternational VErapamil-trandolapril STudy US cohort.
Journal of hypertension. 36(2):419-427 [DOI] 10.1097/HJH.0000000000001559. [PMID] 28938338.
2018
Optimal Systolic Blood Pressure Target in Resistant and Non-Resistant Hypertension: A Pooled Analysis of Patient-Level Data from SPRINT and ACCORD.
The American Journal of Medicine. 131(12):1463-1472.e7 [DOI] 10.1016/j.amjmed.2018.08.005. [PMID] 30142317.
2018
Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.
Hypertension (Dallas, Tex. : 1979). 72(5):e53-e90 [DOI] 10.1161/HYP.0000000000000084. [PMID] 30354828.
2018
Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists.
Cardiovascular diabetology. 17(1) [DOI] 10.1186/s12933-018-0746-4. [PMID] 30016946.
2018
Use of Prescription Medications That Potentially Interfere With Blood Pressure Control in New-Onset Hypertension and Treatment-Resistant Hypertension.
American journal of hypertension. 31(12):1324-1331 [DOI] 10.1093/ajh/hpy118. [PMID] 30052747.
2017
Efficacy and safety of twice- vs once-daily dosing of lisinopril for hypertension.
Journal of clinical hypertension (Greenwich, Conn.). 19(9):868-873 [DOI] 10.1111/jch.13011. [PMID] 28439946.
2017
Resistant Hypertension: Mechanisms and Treatment.
Current hypertension reports. 19(7) [DOI] 10.1007/s11906-017-0754-x. [PMID] 28597403.
2016
Health-related quality of life in persons with apparent treatment-resistant hypertension on at least four antihypertensives.
Journal of human hypertension. 30(3):191-6 [DOI] 10.1038/jhh.2015.61. [PMID] 26084656.
2016
Mortality Risk Associated With Resistant Hypertension Among Women: Analysis from Three Prospective Cohorts Encompassing the Spectrum of Women’s Heart Disease.
Journal of women's health (2002). 25(10):996-1003 [PMID] 27224417.
View on: PubMed
2016
Patient satisfaction with extended-interval warfarin monitoring.
Journal of thrombosis and thrombolysis. 42(4):486-93 [DOI] 10.1007/s11239-016-1385-9. [PMID] 27251646.
2016
Physician-pharmacist collaboration versus usual care for treatment-resistant hypertension.
Journal of the American Society of Hypertension : JASH. 10(4):307-17 [DOI] 10.1016/j.jash.2016.01.010. [PMID] 26852290.
2016
Resistant Hypertension and Susceptible Outcomes: Exploring the Benefits of Aggressive Blood Pressure Control.
Journal of clinical hypertension (Greenwich, Conn.). 18(1):40-2 [DOI] 10.1111/jch.12677. [PMID] 26435037.
2016
Trends in Antihypertensive Medication Use Among US Patients With Resistant Hypertension, 2008 to 2014.
Hypertension (Dallas, Tex. : 1979). 68(6):1349-1354 [PMID] 27777360.
View on: PubMed
2015
Feasibility of Extended-interval Follow-up for Patients Receiving Warfarin.
Cardiovascular therapeutics. 33(3):98-103 [DOI] 10.1111/1755-5922.12115. [PMID] 25786578.
2015
Home blood pressure monitoring with patient-initiated drug titration reduces blood pressure in high-risk patients with hypertension
Evidence-Based Medicine. 20(2) [DOI] 10.1136/ebmed-2014-110109. [PMID] 25587130.
2015
Physician Acceptance of a Physician-Pharmacist Collaborative Treatment Model for Hypertension Management in Primary Care.
Journal of clinical hypertension (Greenwich, Conn.). 17(9):686-91 [DOI] 10.1111/jch.12575. [PMID] 26032586.
2015
Quality of Life in Treatment-Resistant Hypertension.
Current hypertension reports. 17(8) [DOI] 10.1007/s11906-015-0578-5. [PMID] 26115629.
2014
Baseline Predictors of Central Aortic Blood Pressure: a Pear Substudy
Journal of the American Society of Hypertension. 8(3):152-158 [DOI] 10.1016/j.jash.2013.12.008. [PMID] 24629400.
2014
Cardiovascular and mortality risk of apparent resistant hypertension in women with suspected myocardial ischemia: a report from the NHLBI-sponsored WISE Study.
Journal of the American Heart Association. 3(1) [DOI] 10.1161/JAHA.113.000660. [PMID] 24584740.
2014
Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension.
Journal of hypertension. 32(3):635-43 [DOI] 10.1097/HJH.0000000000000051. [PMID] 24299915.
2014
Reply to ‘Resistant hypertension revisited: definition and true prevalence’.
Journal of hypertension. 32(7) [DOI] 10.1097/HJH.0000000000000220. [PMID] 24984184.
2013
A novel endocrinology-based wellness program to reduce medication expenditures and improve glycemic outcomes.
Diabetes & metabolic syndrome. 7(2):87-90 [DOI] 10.1016/j.dsx.2013.02.016. [PMID] 23680247.
2013
Cost-effectiveness of renin-guided treatment of hypertension
American Journal of Hypertension. 26:1303-1310
2013
Integrating virtual reality to expand the public health role of community pharmacists.
Journal of the American Pharmacists Association : JAPhA. 53(2):152-8 [DOI] 10.1331/JAPhA.2013.12200. [PMID] 23571622.
2012
Blood Pressure Responses and Metabolic Effects of Hydrochlorothiazide and Atenolol
American Journal of Hypertension. 25(3):359-365 [DOI] 10.1038/ajh.2011.215. [PMID] 22089105.
2012
Discordance Between Regression-Derived and Atp III Table-Derived Framingham 10-Year Risk: a Path Substudy.
Pharmacotherapy. 32:E184-E185
2012
Potential benefits of warfarin monitoring by a clinical pharmacist in a long term care facility.
Journal of thrombosis and thrombolysis. 33(2):173-7 [DOI] 10.1007/s11239-011-0642-1. [PMID] 21964972.
2011
Carvedilol reduces aortic wave reflection and improves left ventricular/vascular coupling: a comparison with atenolol (CENTRAL Study).
Journal of clinical hypertension (Greenwich, Conn.). 13(12):917-24 [DOI] 10.1111/j.1751-7176.2011.00549.x. [PMID] 22142351.
2011
Dabigatran etexilate: a novel oral thrombin inhibitor for thromboembolic disease.
The Annals of pharmacotherapy. 45(5):603-14 [DOI] 10.1345/aph.1P644. [PMID] 21540406.
2010
Antivirals for influenza: strategies for use in pediatrics.
Paediatric drugs. 12(5):285-99 [DOI] 10.2165/11532530-000000000-00000. [PMID] 20799758.
2010
Thiazide diuretics.
The New England journal of medicine. 362(7):659-60; author reply 660 [PMID] 20187262.
View on: PubMed
2009
Fexofenadine: biochemical, pharmacokinetic and pharmacodynamic properties and its unique role in allergic disorders.
Expert opinion on drug metabolism & toxicology. 5(7):813-22 [DOI] 10.1517/17425250903044967. [PMID] 19545214.
2009
Lack of correlation between thiazide-induced hyperglycemia and hypokalemia: subgroup analysis of results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study
Pharmacotherapy. [DOI] 10.1592/phco.29.10.1157. [PMID] 19792989.
2009
Lack of correlation between thiazide-induced hyperglycemia and hypokalemia: subgroup analysis of results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study.
Pharmacotherapy. 29(10):1157-65 [DOI] 10.1592/phco.29.10.1157. [PMID] 19792989.
2009
Recent changes in the landscape of combination RAS blockade.
Expert review of cardiovascular therapy. 7(11):1373-84 [DOI] 10.1586/erc.09.127. [PMID] 19900020.

Grants

Sep 2018 ACTIVE
Using PCORnet to Compare Blood Pressure Control Strategies
Role: Co-Investigator
Funding: UNIV OF CALIFORNIA SAN FRANCISCO via PATIENT-CENTERED OUTCOMES RES INST
Jul 2018 ACTIVE
Advancing Personalized Hypertension Care through Big Data Science
Role: Principal Investigator
Funding: NATL INST OF HLTH NHLBI
Apr 2015 – Jun 2021
Clinical and Translational Science Institute (CTSI)
Role: Project Manager
Funding: UF DIV OF SPONSORED RES MATCHING FUNDS
Oct 2014 – Sep 2017
Institute of Medicine Anniversary Fellow in Pharmacy
Role: Principal Investigator
Funding: NATL ACAD OF SCIENCES

Education

Graduate Certificate in Biomedical Informatics
2019 · University of Florida
M.P.H.
2011 · University of Florida
Postdoctoral Fellow
2008-2011 · University of Florida
Pharmacy Practice Residency
2007-2008 · NF/SG Veterans Affairs Health System, Gainesville, FL
Pharm.D.
2007 · University of Florida

Teaching Profile

Courses Taught
2015-2020
PHA5007 Pharm and Pop Health
2015-2018
PHA5788 Pharmacotherapy 6
2017
PHA5788C Patient Care 6

Contact Details

Phones:
Business:
(352) 273-5134
Emails:
Business:
ssmith@cop.ufl.edu